AVBP - Company ID 0001868279
The table below shows ArriVent BioPharma, Inc.'s balance sheet line items across its last 2 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 |
|---|---|---|
| Cash & equivalents | $45.54M | $74.29M |
| Short-term investments | $267.28M | $144.57M |
| Receivables | - | - |
| Inventory | - | - |
| Total current assets | $332.90M | $226.98M |
| Property, plant & equipment | - | - |
| Goodwill | - | - |
| Total assets | $333.17M | $274.94M |
| Accounts payable | $5.93M | $3.78M |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Total current liabilities |
| $25.95M |
| $17.27M |
| Long-term debt | - | - |
| Total liabilities | $25.95M | $17.29M |
| Retained earnings | -$404.64M | -$238.33M |
| Total equity | $307.22M | $257.65M |